Scientific Background: J9, in combination with dexamethasone inhibits cell growth in T-cell acute lymphoblastic leukemia (T-ALL) through the upregulation of the glucocorticoid receptor. Patients can develop glucocorticoid resistance rendering the treatment ineffective. J9 and its mechanism of action provides a useful strategy for overcoming the resistance. The EC50 of J9 in combination with dexamethasone is 28 uM. J9 alone was less toxic.